Form 8-K - Current report:
SEC Accession No. 0001104659-25-121674
Filing Date
2025-12-16
Accepted
2025-12-16 17:30:42
Documents
18
Period of Report
2025-12-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2533475d2_8k.htm   iXBRL 8-K 40638
2 EXHIBIT 5.1 tm2533475d2_ex5-1.htm EX-5.1 11495
3 EXHIBIT 10.1 tm2533475d2_ex10-1.htm EX-10.1 268702
8 GRAPHIC tm2533475d2_ex5-1img001.jpg GRAPHIC 19043
9 GRAPHIC tm2533475d2_ex5-1img002.jpg GRAPHIC 14688
10 GRAPHIC tm2533475d2_ex5-1img003.jpg GRAPHIC 3651
  Complete submission text file 0001104659-25-121674.txt   656181

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA huma-20251216.xsd EX-101.SCH 3679
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE huma-20251216_def.xml EX-101.DEF 27100
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE huma-20251216_lab.xml EX-101.LAB 37597
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE huma-20251216_pre.xml EX-101.PRE 25724
20 EXTRACTED XBRL INSTANCE DOCUMENT tm2533475d2_8k_htm.xml XML 5873
Mailing Address 2525 EAST NORTH CAROLINA HIGHWAY 54 DURHAM NC 27713
Business Address 2525 EAST NORTH CAROLINA HIGHWAY 54 DURHAM NC 27713 919-313-9633
Humacyte, Inc. (Filer) CIK: 0001818382 (see all company filings)

EIN.: 851763759 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39532 | Film No.: 251576565
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)